Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.36 |
| ▸ | FEN1 | P39748 | 2/20 | 0.36 |
| ▸ | SCD | O00767 | 2/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
| ▸ | CDK7 | P50613 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | CCNH | P51946 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | POLA1 | P09884 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2951841 | 0.97 | PAK1 (0.55) | PAK1ALDH1A1KDM4ECDK2RXFP1 | |
| SCHEMBL10869151 | 0.95 | PAK1 (0.57) | PAK1ALDH1A1KDM4ECDK2RXFP1 | |
| Hydrochloric Acid SCHEMBL6821631 | 0.95 | PAK1 (0.54) | PAK1ALDH1A1KDM4ECDK2RXFP1 | |
| SCHEMBL31380702 | 0.85 | ALDH1A1 (0.45) | PAK1ALDH1A1KDM4ECDK2RXFP1 | |
| SCHEMBL4373728 | 0.81 | ALDH1A1 (0.44) | PAK1ALDH1A1KDM4ECDK2RXFP1 | |
| SCHEMBL9854792 | 0.77 | ALDH1A1 (0.46) | PAK1ALDH1A1KDM4ECDK2RXFP1 | |
| SCHEMBL2388908 | 0.76 | PAK1 (0.46) | PAK1ALDH1A1KDM4ECDK2RXFP1 | |
| SCHEMBL5872330 | 0.75 | PAK1 (0.45) | PAK1ALDH1A1KDM4ECDK2RXFP1 | |
| SCHEMBL2002538 | 0.75 | PAK1 (0.48) | PAK1ALDH1A1KDM4ECDK2RXFP1 | |
| SCHEMBL2953152 | 0.75 | ALDH1A1 (0.45) | PAK1ALDH1A1KDM4ECDK2RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106305279-A | Comprehensive management and cultivation method for promoting rapid propagation of poplar seedlings | 梁国婷 | 2017-01-11 | — | — | CN | claimed |
| US-9273050-B2 | Cyclobutyl purine derivative, angiogenesis promoting agent, lumen formation promoting agent, neurocyte growth promoting agent, and drug | NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERSITY (JP) | 2016-03-01 | — | — | US | claimed |
| EP-2377865-B1 | CYCLOBUTYL PURINE DERIVATIVE, ANGIOGENESIS PROMOTING AGENT, LUMENIZATION PROMOTING AGENT, NEUROCYTE GROWTH PROMOTING AGENT, AND DRUG | UNIV KAGAWA NAT UNIV CORP (JP) | 2014-12-17 | — | — | EP | claimed |
| CN-102227427-B | Cyclobutyl purine derivative, angiogenesis promoting agent, lumenization promoting agent, neurocyte growth promoting agent, and drug | UNIV KAGAWA NAT UNIV CORP (JP) | 2014-04-02 | — | — | CN | claimed |
| CN-102227427-A | Cyclobutyl purine derivative, angiogenesis promoting agent, lumenization promoting agent, neurocyte growth promoting agent, and drug | UNIV KAGAWA NAT UNIV CORP (JP) | 2011-10-26 | — | — | CN | claimed |
| EP-2377865-A1 | CYCLOBUTYL PURINE DERIVATIVE, ANGIOGENESIS PROMOTING AGENT, LUMENIZATION PROMOTING AGENT, NEUROCYTE GROWTH PROMOTING AGENT, AND DRUG | National University Corporation Kagawa University (JP) | 2011-10-19 | — | — | EP | claimed |
| US-20110230659-A1 | CYCLOBUTYL PURINE DERIVATIVE, ANGIOGENESIS PROMOTING AGENT, LUMEN FORMATION PROMOTING AGENT, NEUROCYTE GROWTH PROMOTING AGENT, AND DRUG | NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERSITY (JP) | 2011-09-22 | — | — | US | claimed |
| US-5874578-A | Process for preparing guanine-containing antiviral agents and purinyl salts useful in such process | BRISTOL-MYERS SQUIBB (US) | 1999-02-23 | — | — | US | claimed |
| CN-1036712-C | Process for preparing guanine-containing antiviral agents and purinyl salts useful in such process | SQUIBB & SONS INC (US) | 1997-12-17 | — | — | CN | claimed |
| CN-1083813-A | Contain guanine antiviral agent the preparation method and be used for the purine salt of this method | SQUIBB & SONS INC (US) | 1994-03-16 | — | — | CN | claimed |
| EP-0579421-A2 | Process for preparing guanine-containing antiviral agents and purinyl salts useful in such process | E.R. Squibb & Sons, Inc. (US) | 1994-01-19 | — | — | EP | claimed |
| US-12202850-B2 | Cyclobutyl purine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2025-01-21 | — | — | US | disclosed |
| US-12202850-B2 | Cyclobutyl purine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2025-01-21 | — | — | US | disclosed |
| US-20230295202-A1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20230295202-A1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2023-09-21 | — | — | US | disclosed |
| EP-0579421-A2 | Process for preparing guanine-containing antiviral agents and purinyl salts useful in such process | E.R. Squibb & Sons, Inc. (US) | 1994-01-19 | — | — | EP | disclosed |
| EP-0554025-A2 | Fluorinated cyclobutyl purines and pyrimidines | E.R. SQUIBB & SONS, INC. (US) | 1993-08-04 | — | — | EP | disclosed |
| WO-1991018969-A1 | FLUORINATED BIS(HYDROXYMETHYL)CYCLOBUTYL PURINES AND PYRIMIDINES | E.R. SQUIBB & SONS, INC. (US) | 1991-12-12 | — | — | WO | disclosed |
| CN-1036575-A | The method of two (methylol) cyclobutyl purine of preparation and pyrimidine | SQUIBB & SONS INC (US) | 1989-10-25 | — | — | CN | disclosed |
| CN-1036575-A | The method of two (methylol) cyclobutyl purine of preparation and pyrimidine | SQUIBB & SONS INC (US) | 1989-10-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295202-A1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | SLC28A1, SLC20A1, SLC29A1 | PAK1 2882/4885ALDH1A1 504/4885KDM4E 4331/4885 |
| US-20110230659-A1 | CYCLOBUTYL PURINE DERIVATIVE, ANGIOGENESIS PROMOTING AGENT, LUMEN FORMATION PROMOTING AGENT, NEUROCYTE GROWTH PROMOTING AGENT, AND DRUG | DCX, MKI67, SLC29A1 | PAK1 2235/4885ALDH1A1 1340/4885KDM4E 4808/4885 |
| US-12202850-B2 | Cyclobutyl purine derivative or salt thereof | SLC28A1, SLC20A1, SLC29A1 | PAK1 2882/4885ALDH1A1 504/4885KDM4E 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.